Tesamorelin / Ipamorelin Blend
Also known as Tesa/Ipa Blend
This blend pairs tesamorelin, a stabilized GHRH analog studied and approved in some jurisdictions for reducing excess visceral fat in a specific clinical population, with ipamorelin, a selective ghrelin-receptor agonist. Tesamorelin has a comparatively strong individual evidence base from randomized clinical trials focused on visceral adipose tissue and body composition, while ipamorelin is added for its complementary GH-pulse-amplifying effect. The combined blend itself, used outside tesamorelin's approved population and indication, has not been studied in controlled trials. It is discussed mainly in the context of body composition and visceral fat research. It is not approved for the general population or for this combined use.
Reported benefits
- Associated with visceral fat reduction based on tesamorelin's studied effects
- Supports body composition changes
- Amplifies overall growth-hormone pulse
- General fat-metabolism research interest
How it works
Tesamorelin stimulates the GHRH receptor with a pharmacokinetic profile designed for consistent daily dosing, and its clinical evidence base centers on reductions in visceral adipose tissue via the GH/IGF-1 axis. Ipamorelin contributes an independent ghrelin-receptor-mediated GH pulse with a comparatively selective side-effect profile. The pairing is described as combining tesamorelin's studied visceral-fat-focused signaling with a broader amplification of the overall GH pulse from ipamorelin.
Dosing ranges
| Tier | Dose | Frequency |
|---|---|---|
| Low | 1,500 mcg | once daily |
| Moderate | 2,200 mcg | once daily |
| High | 3,000 mcg | once daily |
Estimate your dose
Dose estimator
Educational estimate for Tesamorelin / Ipamorelin Blend, scaled to body size. Not medical advice.
Read before using
This tool produces a rough, educational estimate by scaling commonly-published research ranges to lean body mass. It is not a prescription, medical advice, or a substitute for a licensed clinician. Most peptides use fixed dosing, not weight-based dosing. Individual needs vary. You are solely responsible for how you use this information.
Mixing & syringe units
Target dose follows the estimate above. Change it there, or edit it directly below.
Reconstitution calculator
How much water to add and how many insulin-syringe units to draw for Tesamorelin / Ipamorelin Blend. Educational only.
Draw to this mark
44units
= 0.44 mL for a 2,200 mcg dose
Concentration
5,000 mcg/mL
Doses per vial
4
A U-100 syringe reads 100 units per mL. This is a reconstitution math helper only, not a prescription or dosing advice. Verify every calculation and consult a qualified healthcare provider.
Possible side effects
Stacking notes
Tesamorelin's individual evidence base is comparatively strong for visceral fat reduction; the combination with ipamorelin has not itself been evaluated in controlled trials.
Common protocols
Common questions
What is Tesamorelin / Ipamorelin Blend used for?
This blend pairs tesamorelin, a stabilized GHRH analog studied and approved in some jurisdictions for reducing excess visceral fat in a specific clinical population, with ipamorelin, a selective ghrelin-receptor agonist. Tesamorelin has a comparatively strong individual evidence base from randomized clinical trials focused on visceral adipose tissue and body composition, while ipamorelin is added for its complementary GH-pulse-amplifying effect. The combined blend itself, used outside tesamorelin's approved population and indication, has not been studied in controlled trials. It is discussed mainly in the context of body composition and visceral fat research. It is not approved for the general population or for this combined use. Reported benefits include associated with visceral fat reduction based on tesamorelin's studied effects, supports body composition changes, amplifies overall growth-hormone pulse.
What is a typical Tesamorelin / Ipamorelin Blend dose?
Reported ranges run 1,500-3,000 mcg. A low protocol is 1,500 mcg once daily, and a high protocol is 3,000 mcg once daily. This is reference information, not a dosing recommendation.
What is the half life of Tesamorelin / Ipamorelin Blend?
Tesamorelin is reported at approximately 25-40 minutes; ipamorelin at approximately 2 hours. Both are comparatively short-acting, which supports once-daily dosing.. That is what sets the dosing frequency, and it is why the timing guidance is ~30 min before bed, empty stomach.
How is Tesamorelin / Ipamorelin Blend administered?
Subcutaneous: into fat, under the skin. Injected subcutaneously into the abdomen, typically once daily given tesamorelin's short individual half-life; both peptides are commonly combined in one syringe.
How long is a Tesamorelin / Ipamorelin Blend cycle?
12-16 weeks on, followed by 4-6 weeks off. Tesamorelin's studied clinical protocols often run longer than typical secretagogue cycles; shorter informal cycles are commonly referenced outside clinical use.
What are the side effects of Tesamorelin / Ipamorelin Blend?
Reported side effects include injection site reactions, joint or muscle discomfort, water retention, mild elevation in blood glucose (associated with gh-axis stimulation), headache. Evidence level for this compound is well studied.
Partner offer · $20 off
When did you last
check your blood work?
Regular blood work catches changes early. At-home collection with free pickup, 50+ biomarkers, and results in 72 hours.
- 1Order your kitTakes two minutes online, $20 off with this link.
- 2Collect at homePainless draw with free home pickup, no lab visit.
- 3Results in 72 hours50+ biomarkers with clear optimal ranges.
Partner offer · opens rythm.health
Educational use only, not medical advice. This profile is provided for research and educational purposes. Tesamorelin / Ipamorelin Blend may be a research compound or a prescription medication; nothing here is intended to diagnose, treat, cure, or prevent any disease. Dosing figures reflect commonly-published research ranges, not a prescription. Consult a qualified healthcare provider before making any health decision. Read the full disclaimer →